氧氨酸用于治疗反复性口腔平
Prazwala Chirravur1, Herve Sroussi2, Nathaniel Treister2
1Oral Medicine, Oral and Maxillofacial Diagnostic Sciences, UCONN Health, Farmington, CT, USA; Carole and Ray Neag Comprehensive Cancer Center, Farmington, CT, USA.
Oral surgery, oral medicine, oral pathology and oral radiology
|January 26, 2024
概括
氧化 (HCQ) 有效地减少了患者的疼痛和疾病严重程度口腔平坦难治标准治疗. 这项研究强调HCQ作为反抗性OLP病例的可行治疗选择.
科学领域:
- 口腔医学是指口腔医学.
- 皮肤病学 皮肤病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 口腔平坦 (OLP) 是一种慢性炎症状况,影响口腔粘膜.
- 反抗性OLP病例往往对传统疗法反应不佳,需要使用替代治疗策略.
研究的目的:
- 评估氧化 (HCQ) 在对抗抗标准治疗的口腔平坦 (OLP) 的疗效.
- 评估HCQ对OLP患者症状减轻和疾病严重程度的影响.
主要方法:
- 一个单一中心的回顾性研究,涉及耐火性OLP患者,每天两次服用200毫克氧化 (HCQ) 治疗.
- 在基线和随访期间 (12-24个月) 记录了疼痛,网膜,红血和 (REU) 评分.
- 使用t测试进行了统计分析,以比较HCQ治疗前后的得分.
主要成果:
- 36名患者开始接受HCQ治疗,其中30名患者因6名患者的不良事件而可评估.
- 观察到平均最严重疼痛得分的显著下降 (从3.9到1.9,P<.006).
- 平均REU得分也大幅下降 (从16.0降至12.0,P<0.032).
结论:
- 氧化 (HCQ) 是一个有效的治疗选择,用于患者与复发性口腔平坦 (OLP).
- 在没有对标准疗法反应的OLP患者中,HCQ在疼痛和疾病严重性得分方面显著改善.
更多相关视频
相关概念视频
Peptic Ulcer Disease IV: Management
93
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
93
Psychosis: Goals of Pharmacotherapy
131
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
131
Cholinergic Antagonists: Pharmacokinetics
440
Cholinergic antagonists—such as antimuscarinics—are available in oral, topical, ocular, parenteral, and inhalational formulations. Most antimuscarinics are oral formulations, while scopolamine is available as a topical patch, and ipratropium and tiotropium are available as inhalation aerosols or powders. Atropine, tropicamide, and cyclopentolate are topically instilled in the eye. Most antimuscarinics are lipid-soluble and readily absorbed from the gastrointestinal tract and...
440
Hand hygiene
3.2K
Asepsis is the practice of preventing or breaking the chain of infection. The nurse employs aseptic techniques to prevent the spread of microorganisms and reduce the risk of diseases. Hand hygiene is the cornerstone of aseptic techniques and is classified into medical and surgical asepsis. Medical asepsis includes hand hygiene and the use of gloves. Surgical asepsis, or the sterile technique, refers to practices that render and keep objects and areas free of microorganisms.
Hand washing...
Hand washing...
3.2K
Indirect-Acting Cholinergic Agonists: Pharmacokinetics
982
Indirect-acting cholinergic agonists, or anticholinesterases, enhance the body's cholinergic activity by inhibiting acetylcholine's breakdown. They are categorized as reversible or irreversible agents based on their mechanism of action. They are further classified into short-acting, intermediate-acting, and long-acting agents based on their duration of action.
Reversible agents containing quaternary amines, such as neostigmine and edrophonium, are not easily absorbed orally because they...
Reversible agents containing quaternary amines, such as neostigmine and edrophonium, are not easily absorbed orally because they...
982
Antiasthma Drugs: Leukotriene Modifiers
300
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
300


